Targeting lung cancer with immune-modulating T cell therapy
Immune modulating T cell therapy for lung cancer
This study is testing a new treatment for lung cancer that uses specially designed immune cells to deliver a helpful substance directly to the tumors, aiming to improve safety and effectiveness, especially for veterans battling this disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ralph H Johnson VA Medical Center NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project ID | NIH-11052418 on NIH RePORTER |
What this research studies
This research focuses on developing a new type of T cell therapy that delivers a cytokine called Interleukin 12 directly to lung cancer tumors. The approach involves engineering CAR-T cells to target specific proteins associated with lung cancer, namely mesothelin and C3d. A unique method of adoptive transfer is used to ensure that the immune function is preserved, and a novel gene expression system is incorporated to enhance safety and control during treatment. The goal is to validate the safety and effectiveness of this therapy in pre-clinical settings, particularly for veterans suffering from lung cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are veterans diagnosed with lung cancer who may benefit from innovative immune therapies.
Not a fit: Patients with lung cancer who are not veterans or those who do not respond to immune-modulating therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for lung cancer patients, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in using CAR-T cell therapies for various cancers, indicating potential success for this novel approach in lung cancer treatment.
Where this research is happening
Charleston, United States
- Ralph H Johnson VA Medical Center — Charleston, United States (Active)
Researchers
- Principal investigator: O'neil, Richard Thomas — Ralph H Johnson VA Medical Center
- Study coordinator: O'neil, Richard Thomas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.